The linked FDA record identifies Trisalus Life Sciences as applicant for K253509, the TriNav Advance Infusion System, received November 5, 2025 and decided September 21, 2026 as substantially equivalent under a traditional 510(k) with a summary. The filing lists product code KRA, regulation 870.1210, device class 2 and the cardiovascular advisory committee. The applicant address on the filing is in Westminster, Colorado; that is a filing address, not a verified headquarters. The MedtechLedger collection holds one linked record, a 510(k) with a substantially equivalent decision, and the record sample contains that same single entry. [1][2][4]

The cleared device and its stated scope

The FDA clearance letter describes the TriNav Advance Infusion System as intended for use in angiographic procedures, delivering radiopaque media and therapeutic agents. The FDA record classifies the device as a continuous-flush catheter within the cardiovascular medical specialty. The company's own announcement, published September 22, 2026, places TriNav Advance in its Pressure-Enabled Drug Delivery portfolio for liver embolization. [4][1][7]

The TriNav Advance clearance is the only filing in the supplied collection, so it defines the documented regulatory footprint here. The record shows a third-party review flag and a summary statement, and the FDA notification page repeats the September 21, 2026 decision date and the substantially equivalent outcome. [1][2]

Product family as published by the company

TriSalus publishes instructions for use covering TriGuide Guiding Catheter and TriNav FLX with SmartValve Technology, and its resource library lists TriNav, TriNav Advance, TriNav FLX, TriNav LV, TriNav XP and TriGuide Guiding Catheter as product types. The company states that TriNav Infusion Systems are not intended for use in the vasculature of the central nervous system or the central circulatory system, including the coronary vasculature, and are marked Rx Only. [3][6]

Company pages describe TriNav Infusion Systems as a portfolio for interventional radiologists addressing a range of vessel anatomy, with recommended vessel sizes of 1.5–3.5 mm stated for TriNav and TriNav FLX. TriSalus states that its devices use the Pressure-Enabled Drug Delivery method to address intratumoral pressure through modulation of pressure and flow, and that it has two FDA-cleared devices. These are company descriptions, not independently verified performance results. [5][9]

Applicant identity and corporate context

The FDA filing names Trisalus Life Sciences as applicant, with a contact and an address in Westminster, Colorado, and the clearance letter is addressed to the same applicant. The company's clearance announcement identifies TriSalus Life Sciences, Inc. (Nasdaq: TLSI) and describes it as an oncology company integrating delivery technology with standard-of-care therapies and an investigational immunotherapeutic. The announcement is the source for that corporate description and the ticker; the FDA record does not establish ownership or brand relationships. [1][4][7]

The company's technology page states that the TriSalus drug delivery devices use the proprietary Pressure-Enabled Drug Delivery method and that the company currently has two FDA-cleared devices. The supplied collection documents one 510(k) record, so it does not enumerate the full cleared portfolio. [9]

What the supplied record does and does not show

The collection snapshot contains one linked record, a 510(k) with a substantially equivalent decision, and the record sample contains that same single entry. These counts describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio size or safety performance. No recall records appear in the supplied sample. [1]

The public documents do not establish headquarters, ownership structure, customers, commercial availability, clinical outcomes or certifications beyond the FDA clearance and the company's own published statements. The FDA notification page and clearance letter support the decision date, decision type and device identity; other product details rest on company publications. [2][4][3]